-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
4D Molecular Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2020 to Q2 2024.
- 4D Molecular Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $7.5M, a 198% increase year-over-year.
- 4D Molecular Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $21.3M, a 250% increase year-over-year.
- 4D Molecular Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $12M, a 374% increase from 2022.
- 4D Molecular Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $2.54M, a 15763% increase from 2021.
- 4D Molecular Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was $16K.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)